As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring ...
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access expands through telehealth — here is what the RenuviaRX platform model, ...
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...
Study Finds on MSN
Injectable filler made from donated skin shows promise for breast reconstruction in cancer patients
In A Nutshell Korean researchers developed SC Fill paste, an injectable tissue filler made from processed human skin that ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...
Mosunetuzumab's subcutaneous formulation offers a 1-minute injection, improving convenience over the previous intravenous infusion for relapsed or refractory follicular lymphoma. The phase 1/2 GO29781 ...
Botox can cause temporary redness, swelling, tenderness, or bruising at the injection site. You may get flu-like symptoms like fever, body aches, or nausea after Botox. Botox may cause headaches, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback